CVS Health (CVS) — Q2 2026 Earnings Preview
Key Factors to Watch This Quarter
| Factor | Details | Importance |
|---|---|---|
| 2026 Adjusted EPS Guidance | Raised to $7.30–$7.50 (from $7.00–$7.20) after Q1; consensus for FY26 is $7.32 | High — sets tone for full-year profitability trajectory |
| Revenue Growth | Q2 consensus: $100,068M (+5.3% YoY); Q1 actual: $100,426M (+6.2% YoY) | High — signals demand and execution across segments |
| Health Care Benefits (HCB) Margin Recovery | Q1 AOI up +53% YoY; 2026 AOI guidance raised to $4.0–$4.34B; MBR guided at 90.5% ±50bps | High — margin recovery is central to multi-year thesis |
| Pharmacy & Consumer Wellness (PCW) Segment | Q1 AOI down -9% YoY but FY26 AOI guidance raised to $6.18B; script growth, CostVantage rollout | Medium — stability/expansion of retail pharmacy margins |
| Health Services (HSS) Segment | Q1 AOI down -7% YoY; full-year guide reiterated; rebate guarantee pressure in focus | Medium — PBM performance and regulatory risk |
| Medical Cost Trends | Management maintains a “prudent” view; Q1 MBR outperformed at 84.6% | High — cost trend surprises are a sector-wide risk |
| Cash Flow from Operations | FY26 guidance raised to at least $9.5B | Medium — supports deleveraging and future capital returns |
| Regulatory/Legislative Impact | PBM reform, state-level actions (e.g., Tennessee), IRA/MFN drug pricing | High — could affect PBM and retail economics |
| AI/Tech Investment Payoff | Health100 platform launch, ongoing AI-driven efficiency | Medium — long-term differentiator, near-term cost/investment impact |
Recent Results and Year-Over-Year Comparison
Quarterly Financials — Actuals vs. Consensus
| Quarter | Revenue ($M) | YoY Growth | Adj. EPS | YoY Growth | Cash Flow from Ops ($M) |
|---|---|---|---|---|---|
| Q1 2026 | 100,426 | +6.2% | $2.57 | +14.2% | 4,249 |
| Q2 2025 | 98,915 | +8.4% | $1.81 | -1.1% | 6,453 |
| Q2 2026E (consensus) | 100,068 | +5.3% |
Note: Q2 2025 was a strong comp with high revenue growth but flat EPS due to litigation charges and segment mix.
Full-Year Financials — Actuals and Guidance
| Fiscal Year | Revenue ($M) | YoY Growth | Adj. EPS | YoY Growth | Cash Flow from Ops ($M) |
|---|---|---|---|---|---|
| 2025 (actual) | 402,067 | +7.8% | $6.75 | +24.5% | 10,639 |
| 2026E (guidance) | ≥405,000 | +0.7% | $7.30–$7.50 | +8.1%–+11.1% | ≥9,500 |
Segment Performance — Q1 2026
| Segment | Revenue ($M) | Adj. Operating Income ($M) | YoY Growth (AOI) | Key Commentary |
|---|---|---|---|---|
| Health Care Benefits | 35,971 | 3,041 | +52.6% | Margin recovery, MBR 84.6% |
| Health Services | 48,237 | 1,489 | -7.1% | Rebate guarantee pressure, PBM transition |
| Pharmacy & Consumer Wellness | 31,989 | 1,197 | -8.8% | CostVantage rollout, script growth |
| Consolidated | 100,426 | 5,150 | +12.5% | Strong HCB offsetting HSS/PCW headwinds |
Guidance Summary
2026 Guidance (as of Q1 2026)
| Metric | Guidance | Prior Guidance | Change | Notes |
|---|---|---|---|---|
| Revenue ($M) | ≥405,000 | ≥400,000 | +$5,000M | All segments contributing |
| Adj. EPS | $7.30–$7.50 | $7.00–$7.20 | +$0.30 | Driven by HCB, PCW |
| GAAP EPS | $6.24–$6.44 | $5.94–$6.14 | +$0.30 | |
| Cash Flow from Ops ($M) | ≥9,500 | ≥9,000 | +$500M | Working capital improvement |
| HCB AOI ($M) | 4,000–4,340 | 3,580–3,920 | +$420M | Margin recovery, PYD benefit |
| HCB MBR | 90.5% ±50bps | 90.5% ±50bps | Prudent trend assumption | |
| PCW AOI ($M) | ≥6,180 | ≥6,090 | +$90M | Script growth, CostVantage |
| HSS AOI ($M) | Unchanged | Unchanged | Rebate guarantee pressure persists |
